About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNANCT01798966

Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease

Patients with Thyroid Eye Disease (TED) often have enlarged extraocular muscles and higher orbital fat contents due to their disease process. The confined space of the orbit cannot hold the enlarged o...

Lead sponsor: Sensimed AG•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Sensimed AG

Collaborators

University of California, San Diego

Age

18 - 90 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Subject is able to comply with the study procedures
•18-80 years old
•Subjects diagnosed with Thyroid Eye Disease based on both endocrinology studies showing autoimmune dysfunction consistent with Graves' Disease as well as orbital imaging studies manifesting characteristics consistent with Thyroid Eye Disease.
•Ability to understand the character and individual consequences of the study
•Subject has consented to be in the trial

Exclusion Criteria

•Subjects with contraindications for wearing contact lenses
•Severe ocular surface disease
•Keratoconus or other corneal abnormality
•Severe ocular inflammation
•Full frame metal glasses during SENSIMED Triggerfish® monitoring
•Known hypersensitivity to silicone, plaster or ocular anesthesia (proparacaine)
•Simultaneous participation in other clinical studies
•Diagnosis of glaucoma

Related studies

Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease

NCT07400757 · Thyroid Eye Disease, TED, Graves Ophthalmopathy

RECRUITINGPhase 3

Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease

NCT07262476 · Thyroid Eye Disease (TED)

Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.

NCT07423013 · Thyroid Eye Disease

RECRUITINGPhase 2/3

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

NCT06112340 · Thyroid Eye Disease, Graves Orbitopathy, and more

Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease

NCT06359795 · Thyroid Eye Disease

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 11, 2016Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment10

Start dateFeb 2013

Last updatedMar 11, 2016

Condition

Thyroid Eye Disease

Locations shown

Shiley Eye Center, University of California, San Diego

La Jolla, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 11, 2016Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions